In 2020, the US Food and Drug Administration (FDA) approved the fixed-dose combination (pertuzumab, trastuzumab, and hyaluronidase-zzxf) with chemotherapy as neoadjuvant therapy for patients with early or locally advanced, inflammatory HER2+ breast cancer, and for high-risk patients with early HER2+ breast cancer (33). The gene discussed is ERBB2; the disease is breast carcinoma.